Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

JAMP NINTEDANIB DIN 02550849

Status: Marketed
Holder: JAMP PHARMA CORPORATION
Molecule: NINTEDANIB (NINTEDANIB ESILATE)
Available to quote

Health Canada record

Active ingredient(s)NINTEDANIB (NINTEDANIB ESILATE) 100 MG
Dosage formCapsule
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCL01EX09 NINTEDANIB
Original market date22-Dec-2025
Current status date22-Dec-2025
SourceHealth Canada DPD

Establishment licence of the holder

Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating I (2026-09-16).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing NINTEDANIB (NINTEDANIB ESILATE)

DINProductCompanyFormStrengthStatus
02526891AURO-NINTEDANIBAURO PHARMA INCCapsuleNINTEDANIB (NINTEDANIB ESILATE) 100 MGMarketed
02526905AURO-NINTEDANIBAURO PHARMA INCCapsuleNINTEDANIB (NINTEDANIB ESILATE) 150 MGMarketed
02547538EUGIA-NINTEDANIBEUGIA PHARMA INC.CapsuleNINTEDANIB (NINTEDANIB ESILATE) 150 MGApproved
02547511EUGIA-NINTEDANIBEUGIA PHARMA INC.CapsuleNINTEDANIB (NINTEDANIB ESILATE) 100 MGApproved
02569221GLN-NINTEDANIBGLENMARK PHARMACEUTICALS CANADA INC.CapsuleNINTEDANIB (NINTEDANIB ESILATE) 100 MGApproved
02569248GLN-NINTEDANIBGLENMARK PHARMACEUTICALS CANADA INC.CapsuleNINTEDANIB (NINTEDANIB ESILATE) 150 MGApproved
02540762JAMP NINTEDANIBJAMP PHARMA CORPORATIONCapsuleNINTEDANIB (NINTEDANIB ESILATE) 150 MGMarketed
02443066OFEVBOEHRINGER INGELHEIM (CANADA) LTD LTEECapsuleNINTEDANIB (NINTEDANIB ESILATE) 100 MGMarketed
02443074OFEVBOEHRINGER INGELHEIM (CANADA) LTD LTEECapsuleNINTEDANIB (NINTEDANIB ESILATE) 150 MGMarketed

Notices of Compliance

NOCDateSubmissionReason
364572025-12-01Supplement to an Abbreviated New Drug Submission (SANDS)Addition of new strength: Addition of 100 mg Nintedanib capsules
Request a quote for JAMP NINTEDANIB

How to read a Canadian DIN record